Выбор темы
Выбор стиля шрифта
Bristol-Myers новости
15/06
BMY - Сделка Инсайдера: продажа 13 июня 2022
08/06
BMY - Сделка Инсайдера: продажа 06 июня 2022
19/03
BMY - Сделка Инсайдера: продажа 16 марта 2022
17/03
BMY - Сделка Инсайдера: продажа 14 марта 2022
17/03
BMY - Сделка Инсайдера: продажа 14 марта 2022
01/03
BMY - Сделка Инсайдера: продажа 24 февраля 2022
03/02
🔗
Zacks Investment Research: Drug/Biotech Stock Q4 Earnings Due on Feb 4: BMY, REGN & SNY
31/01
🔗
Zacks Investment Research: Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store?
31/01
🔗
The Motley Fool: Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?
29/01
🔗
Zacks Investment Research: Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
29/01
🔗
Zacks Investment Research: Bristol Myers Squibb (BMY) Earnings Expected to Grow: Should You Buy?
18/01
🔗
Forbes: Is Bristol Myers Squibb Stock A Better Pick Over This Vaccine Company?
17/01
🔗
Seeking Alpha: Bristol Myers Squibb Looks Strong In 2022, Century Deal Can Help Establish Cell Therapy Leadership
14/01
🔗
The Motley Fool: 4 Biotech Acquisitions We'd Like to See in 2022
11/01
🔗
Seeking Alpha: Bristol Myers Squibb Shares Are Still Undervalued
11/01
🔗
Zacks Investment Research: Bristol Myers Squibb (BMY) Recently Broke Out Above the 200-Day Moving Average
11/01
🔗
GeekWire: Bristol Myers Squibb and Century Therapeutics' deal for $150M could boost Seattle cell research
10/01
🔗
Invezz: Expert opinion: ‘Bristol-Myers is a buy'
10/01
🔗
CNBC Television: This is the time to buy Bristol Myers, says Jim Lebenthal
10/01
🔗
CNBC Television: We have an accelerated opportunity to renew our portfolio, says Bristol Myers Squibb CEO
10/01
🔗
Benzinga: Bristol Myers Squibb Shares Jump After J.P. Morgan Healthcare Conference Presentation
10/01
🔗
Seeking Alpha: Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at JPMorgan 40th Annual Healthcare Brokers Conference (Transcript)
10/01
🔗
Zacks Investment Research: Bristol Myers Squibb (BMY) Crossed Above the 20-Day Moving Average: What That Means for Investors
10/01
🔗
Benzinga: Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies
30/12
🔗
InvestorPlace: Best Stocks for 2022: Bristol-Myers Squibb Will Offer Huge Returns
30/12
🔗
Seeking Alpha: Bristol-Myers Squibb Vs. Merck Stock: Which Is The Better Buy?
28/12
🔗
Seeking Alpha: Bristol Myers: Disciplined Investors Shall Be Rewarded
28/12
🔗
Seeking Alpha: Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching
22/12
🔗
Zacks Investment Research: Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
21/12
🔗
The Motley Fool: Bristol Myers Squibb Stock: Bull vs. Bear
17/12
🔗
The Motley Fool: Here's Why Shares of Bristol Myers Squibb, Eli Lilly, and Pfizer Rocketed Higher This Week
17/12
🔗
Invezz: Bristol-Myers Squibb stock forecast after announcing $15 billion buyback
16/12
🔗
Zacks Investment Research: Bristol Myers' (BMY) Orencia Gets FDA Nod for New Indication
15/12
🔗
Seeking Alpha: It's A Good Time To Buy Bristol Myers Squibb
14/12
🔗
GuruFocus: Muhlenkamp's Firm Buys Equity Commonwealth, Dumps 2 Stocks
13/12
🔗
Benzinga: Why Bristol-Myers Squibb Shares Are Rising Today
13/12
🔗
Market Watch: Bristol Myers Squibb raises quarterly dividend and adds $15 billion to share buyback program
13/12
🔗
Benzinga: Bristol Myers Reveals Full Data For Breyanzi In Second-Line Lymphoma Setting
10/12
🔗
Seeking Alpha: 2 Dividend Bargains Piquing My Interest
06/12
🔗
Zacks Investment Research: Bristol Myers (BMY) sBLA for Reblozyl Gets Priority Review
06/12
🔗
Seeking Alpha: Bristol-Myers Squibb: Underperformance Is Temporary
03/12
🔗
Benzinga: Bristol Myers - Merck's Thalassemia Candidate Under FDA Priority Review
03/12
🔗
Forbes: Is A Rise Imminent For Bristol Myers Squibb Stock?
03/12
🔗
The Motley Fool: 2 Absurdly Cheap Growth Stocks to Buy in December
02/12
🔗
Reuters: Bristol Myers is sued for refusing COVID-19 vaccine religious exemptions
01/12
🔗
Zacks Investment Research: Bristol Myers' (BMY) Plaque Psoriasis Drug Filings Get Through
29/11
🔗
Zacks Investment Research: Bristol Myers (BMY) Top Drugs Maintain Momentum Amid Competition
29/11
🔗
Benzinga: Bristol Myers' Deucravacitinib Under FDA Review For Plaque Psoriasis
29/11
🔗
Seeking Alpha: Bristol-Myers: Value Time Again
28/10
МНЕНИЕ: Прогнозы по Bristol Myers остаются в силе после квартальной отчетности - Финам
Загрузить еще